TY - JOUR
T1 - Comparison of dietary and lifestyle habits among stage III and metastatic colorectal cancer patients
T2 - Findings from CALGB 89803 and CALGB 80405
AU - Van Loon, Katherine
AU - Wigler, Devin
AU - Niedzwiecki, Donna
AU - Venook, Alan P.
AU - Fuchs, Charles
AU - Blanke, Charles
AU - Saltz, Leonard
AU - Goldberg, Richard M.
AU - Meyerhardt, Jeffrey A.
N1 - Funding Information:
The research for CALGB 89803 and 80405 was supported, in part, by grants from the National Cancer Institute ( CA31946 ) to the Cancer and Leukemia Group B (Monica M. Bertagnolli, MD, Chair) and to the CALGB Statistical Center (Daniel J. Sargent, PhD, CA33601 ), and support from Pharmacia & Upjohn Company, now Pfizer Oncology, Sanofi-Aventis, and Bristol-Myers Squibb. These analyses were also supported by R01CA118553 (PI, Fuchs), R01CA14922 (PI, Meyerhardt), and P50 CA127003 (PI, Fuchs). The content of this manuscript is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute.
PY - 2013/6
Y1 - 2013/6
N2 - Background: Cancer patients often pursue lifestyle and dietary changes with the aim to improve outcomes. Using data from 2 large National Cancer Institute-sponsored clinical trials, we report on the dietary and lifestyle practices of patients receiving therapy for stage III colon or metastatic colorectal cancer. Patients and Methods: Self-administered questionnaires were completed by patients undergoing chemotherapy for stage III colon cancer (n = 1095) and metastatic colorectal cancer (n = 875). Descriptive statistical analyses were performed to evaluate anthropometrics, diet, and lifestyle in each cohort. Results: Median body mass index was comparable for stage III and metastatic patients (27.3 vs. 26.5 kg/m2). Stage III patients reported a modestly higher median level of physical activity than metastatic patients (4.6 vs. 3.4 metabolic equivalent task-hours per week). Ten percent of stage III and 9% of metastatic patients reported ongoing cigarette use. Avoidance of alcohol was reported by 47% of stage III and 43% of metastatic patients. Dietary patterns for both groups were comparable with more than 80% of stage III and metastatic patients failing to meet the recommended daily intake of vegetables, fruits, and milk products. Usage of at least 2 multivitamins per week was reported by 49% of stage III and 40% of metastatic patients. Two percent of stage III and 5% of metastatic patients reported vitamin D supplement use. Conclusions: We observed notable similarities in dietary and lifestyle behaviors between stage III colon and metastatic colorectal cancer patients actively receiving chemotherapy. Future research should aim to elucidate the effect of these behaviors on patient outcomes.
AB - Background: Cancer patients often pursue lifestyle and dietary changes with the aim to improve outcomes. Using data from 2 large National Cancer Institute-sponsored clinical trials, we report on the dietary and lifestyle practices of patients receiving therapy for stage III colon or metastatic colorectal cancer. Patients and Methods: Self-administered questionnaires were completed by patients undergoing chemotherapy for stage III colon cancer (n = 1095) and metastatic colorectal cancer (n = 875). Descriptive statistical analyses were performed to evaluate anthropometrics, diet, and lifestyle in each cohort. Results: Median body mass index was comparable for stage III and metastatic patients (27.3 vs. 26.5 kg/m2). Stage III patients reported a modestly higher median level of physical activity than metastatic patients (4.6 vs. 3.4 metabolic equivalent task-hours per week). Ten percent of stage III and 9% of metastatic patients reported ongoing cigarette use. Avoidance of alcohol was reported by 47% of stage III and 43% of metastatic patients. Dietary patterns for both groups were comparable with more than 80% of stage III and metastatic patients failing to meet the recommended daily intake of vegetables, fruits, and milk products. Usage of at least 2 multivitamins per week was reported by 49% of stage III and 40% of metastatic patients. Two percent of stage III and 5% of metastatic patients reported vitamin D supplement use. Conclusions: We observed notable similarities in dietary and lifestyle behaviors between stage III colon and metastatic colorectal cancer patients actively receiving chemotherapy. Future research should aim to elucidate the effect of these behaviors on patient outcomes.
KW - Behavioral patterns
KW - Chemotherapy
KW - Colon cancer
KW - Exercise
KW - Nutrition
UR - http://www.scopus.com/inward/record.url?scp=84876842184&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84876842184&partnerID=8YFLogxK
U2 - 10.1016/j.clcc.2012.11.002
DO - 10.1016/j.clcc.2012.11.002
M3 - Article
C2 - 23317558
AN - SCOPUS:84876842184
SN - 1533-0028
VL - 12
SP - 95
EP - 102
JO - Clinical Colorectal Cancer
JF - Clinical Colorectal Cancer
IS - 2
ER -